The other GLP-1-type medications are known for sharing some common side effects, and the clinical trials of retatrutide have shown that participants are experiencing these as well
Rybelsus , another product from Novo Nordisk, offers an oral option for GLP-1 therapy
As a modified version of the naturally occurring GLP-1 hormone, semaglutide has a 94% amino acid sequence homology to human GLP-1 but includes strategic modifications that extend its half-life to approximately one week, enabling once-weekly dosing
Molecular size, enzymatic degradation, saliva, short contact time, and the mucosal barrier can all limit uptake
It did find that the percentage of weight lost from muscle mass was similar between the groups, while the semaglutide group lost more mass overall